Stock analysts at Raymond James Financial have revised their price target for Abbott Laboratories (NYSE: ABT) from $146.00 to $130.00, as reported on January 22, 2026. Despite the downgrade, the brokerage maintains an “outperform” rating on the healthcare company, suggesting potential upside of approximately 19.61% from the stock’s previous close.
The adjustment from Raymond James comes amid a series of mixed evaluations from other analysts. Daiwa Capital Markets raised their price target from $134.00 to $136.00, reaffirming an “outperform” rating. In contrast, the Goldman Sachs Group lowered its price objective from $152.00 to $140.00, while maintaining a “buy” rating. Barclays also revised its forecast, increasing its target from $162.00 to $169.00 and assigning an “overweight” rating. Meanwhile, Sanford C. Bernstein raised its target from $150.00 to $154.00, and BTIG Research reduced its target from $145.00 to $140.00 with a “buy” rating.
Analysts remain generally optimistic about Abbott Laboratories. According to MarketBeat.com, the consensus rating is “Moderate Buy,” with an average target price of $143.37. Out of 22 research analysts, two have issued a Strong Buy rating, seventeen have given a Buy rating, and three have issued a Hold rating.
Recent Earnings Performance
Abbott Laboratories recently reported its earnings results for the fourth quarter, revealing earnings per share (EPS) of $1.50, aligning with market expectations. The company generated revenue of $11.46 billion, slightly below the consensus estimate of $11.80 billion. This represents a year-over-year revenue increase of 4.4%.
Furthermore, Abbott Laboratories provided guidance for the first quarter of fiscal year 2026, projecting EPS between $1.120 and $1.180, with an annual guidance of $5.550 to $5.800. Analysts forecast an average EPS of $5.14 for the current fiscal year.
Institutional Investment Trends
Recent changes in institutional ownership reflect a growing interest in Abbott Laboratories. IMG Wealth Management Inc. significantly increased its position by 759.1% during the second quarter, now holding 189 shares valued at approximately $26,000. Other investors, like Harbor Capital Advisors Inc. and Cloud Capital Management LLC, have also made significant purchases, indicating strong institutional demand.
Currently, approximately 75.18% of Abbott Laboratories’ stock is owned by institutional investors, highlighting the company’s appeal as a stable investment in the healthcare sector.
Abbott Laboratories, headquartered in Abbott Park, Illinois, has a rich history dating back to 1888. The company develops and markets a diverse range of medical products and services, focusing on diagnostics, medical devices, nutritionals, and established pharmaceuticals. With a commitment to innovation, Abbott aims to provide healthcare solutions that address a wide array of health conditions, serving hospitals, clinics, and consumers alike.
